Becton Dickinson (BDX)
Health Care · Medical Devices and Diagnostics · NYSE
A global medical technology leader providing essential healthcare supplies, diagnostic systems, and biosciences research tools to improve patient outcomes.
What Becton Dickinson does
Becton Dickinson is a global medical technology company engaged in the development, manufacture, and sale of a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. The company focuses on improving medical discovery, diagnostics, and the delivery of care through its comprehensive portfolio of healthcare solutions.
Themes: medical technology, diagnostics, clinical laboratory solutions, healthcare delivery efficiency, biosciences research
Fundamentals
- Price$192.00 as of 2026-08-21 close
- Market cap$52.3B as of 2026-08-21
- 1-year return+24.2% 2025-08-21 close $154.58 → 2026-08-21 close $192.00
- P/E53.21 as of 2026-08-24
- Net margin+4.5% as of 2026-08-24
- Gross margin+46.7% as of 2026-08-24
- ROE+3.8% as of 2026-08-24
- Debt / equity0.69 as of 2026-08-24
- Revenue growth (YoY)-2.6% as of 2026-08-24
- Revenue CAGR (3y)+5.0% SEC XBRL
- Beta0.22 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +1.6%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How BDX compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
BDX is not currently in any published Top 10 list. Its scores are below.
Long-term score
45.8 #657 of 987 scored · #40 of 57 in Health Care
Long-term trend 76th (a strong uptrend, with buyers in control) and capital return 71st (consecutive years of dividend increases 5 years); weakest is profitability (21st, return on equity 3.8%, operating margin 9.6%).
Short-term score
49.4 #829 of 1,704 scored · #145 of 240 in Health Care
Trend 79th: a strong uptrend, with buyers in control; volume and participation 78th: trading volume is about normal versus its 30-day average; weakest is setup 31st: over the past year its closes ranged, and it has retraced essentially none of its move over the past year — 0% of it. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, BDX's dividend was covered by reported results (earnings payout 71%, free-cash-flow payout 45%). This describes past coverage, not a forecast.
- Earnings payout71% dividends / net income
- Free-cash-flow payout45% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Becton Dickinson looks technically
Becton Dickinson (BDX) is trading 21.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 8 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 47, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 78, in overbought territory (above 70). It just made a new 20-day high, pushing above its recent trading range. It is trading right at its highest price of the past year (its 52-week high).
Trend
9
| Distance from the 200-day | it is trading 21.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +21.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $161.49 | $161.49 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $157.53 | $157.53 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 35 calendar days ago — the swings before that are what the structure reading is measured on | 35 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 159.47. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 8 trading days ago — a "golden cross", a bullish long-term signal | 8 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 21.9% above | +21.9% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 47, with buyers in control | 47.4 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 78, in overbought territory (above 70) | 78.5 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($166.80 to $192.30) — its "stochastic" reading is 99 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 98.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 20 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $192.30 | $192.30 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.2% |
| Above the 52-week low | it is 50.5% above its 52-week low (its lowest price of the past year) | +50.5% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.2% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $225.88 (set on 2023-07-24) | $225.88 |
| Given back of the 52-week move | over the past year its closes ranged ($138.67 to $192.00), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $157.34 to $159.04. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 15.0% below its all-time high | -15.0% |
| Nearest price level | it is sitting right on a resistance level at $192.18 — a price it turned at four times since 2024-09-03, most recently on 2024-11-06. Since 2024-08-21 it has 11 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.1% |
| All-time low | its lowest closing price on record is $14.19 (set on 1996-11-22) | $14.19 |
| Above the all-time low | it is 1253.1% above its all-time low | +1,253% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 81% of the past ~6 months) | 81st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.54 between its high and its low — about 2.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.54 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $158.99 and $193.99 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $158.99 – $176.49 – $193.99 |
| Typical daily range (% of price) | its price moves about 2.4% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.4% |
| Stretch from the 200-day average | it is trading 7.6 daily ranges above its 200-day average price (21.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.47× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.3% since the prior reading | +1.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Open gap | it gapped 3.1% above the previous close 11 sessions ago and has not traded back through the level it left behind at 170.66 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.1% |
| Gap filled | a 2.3% gap up opened on 2026-06-04 has been "filled" 47 sessions ago — price traded back through the level the gap left behind, and it took 4 sessions to close | 47 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +6.21% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 22.5 percentage points (the stock gained 24.8% while the market gained 2.3%) | +22.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 28.2 percentage points (the stock gained 31.3% while the market gained 3.1%) | +28.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 7.5 percentage points (the stock gained 3.6% while the market gained 11.1%) | -7.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 3.7 percentage points (the stock gained 24.2% while the market gained 20.5%) | +3.7% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 26% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.1% of the share price, which is taken to mean a barrier that gives way easily. | +26.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 21% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $159.32 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +20.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $182.86 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +5.0% |
Price levels it has turned at before
BDX last closed at $192.00 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $192.18 | Resistance | 0.1% above the last close | turned there four times · 2024-09-03 to 2024-11-06 |
| $183.55 | Support | 4.4% below the last close | turned there five times · 2024-10-10 to 2025-03-19 |
| $179.15 | Support | 6.7% below the last close | turned there three times · 2024-09-11 to 2025-01-15 |
| $173.70 | Support | 9.5% below the last close | turned there five times · 2024-11-19 to 2025-03-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $159.47.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $159.47 and $159.62 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.07 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$194.42 range $170.00 – $225.00; median $192.50
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BDX
- Consensus EPS estimate$4.07 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Integration, restructuring, and transaction expenses related to organizational changes or acquisitions.","Potential for asset impairment charges affecting financial performance.","Exposure to fluctuations in foreign currency translation."]
What changed in the latest 10-Q
AI-assisted comparison of BDX's 10-Q filed 2026-05-07 against the prior one filed 2026-02-09.
Management's Discussion & Analysis (MD&A)
- Added:
- Added disclosure that the spin-off was completed on February 9, 2026, and that historical results of the former Biosciences and Diagnostic Solutions business have been reflected as discontinued operations in consolidated financial statements for all periods prior to the spin-off date (filed 2026-05-07)
- Added reference to Note 2 regarding spin-off disclosures (filed 2026-05-07)
- Added statement that post-separation, the Life Sciences segment was eliminated from segment reporting structure, and new structure consists of four remaining segments (filed 2026-05-07)
- Added disclosure about the ongoing conflict in Iran and the Middle East region and its potential impact on supply chain (filed 2026-05-07)
- Added detail that tariffs adversely impacted second quarter fiscal year 2026 operating expense (filed 2026-05-07)
- Added disclosure about developments regarding refunds of certain tariffs being monitored (filed 2026-05-07)
- Removed:
- Removed reference to 'laboratory equipment and diagnostic products' from Company Overview description (filed 2026-02-09)
- Removed reference to 'life science researchers' from list of users (filed 2026-02-09)
- Removed disclosure that five distinct segments were established, including Life Sciences segment (filed 2026-02-09)
- Removed prospective language stating that Life Sciences segment 'will be eliminated' and results 'will be reflected' as discontinued operations (filed 2026-02-09)
- Removed reference to Note 7 regarding segment structure (filed 2026-02-09)
- Removed disclosure about reductions or delays in governmental research funding causing customers to delay or forgo purchases (filed 2026-02-09)
- Removed reference to the government's focus to 'contain its healthcare-related costs' in China market dynamics description (filed 2026-02-09)
- Removed statement that tariffs adversely impacted first quarter fiscal year 2026 operating expense (filed 2026-02-09)
- Removed language stating tariffs 'also' could adversely impact supply chain costs (filed 2026-02-09)
- Reworded:
- Changed reference from Note 7 to Note 8 regarding segment structure and income presentation (filed 2026-05-07)
- Changed from prospective 'will be reflected as discontinued operations' and 'will be eliminated' to past tense 'have been reflected as discontinued operations' and 'eliminated' (filed 2026-05-07)
- Changed description of China market dynamics from 'improve compliance' to 'contain its healthcare-related costs and to improve compliance' (filed 2026-05-07)
- Reordered sentence about tariffs to introduce Iran and Middle East conflict as separate paragraph before tariffs discussion (filed 2026-05-07)
- Notes:
- Text in newer filing appears truncated at end ('For additional informatio'), making complete comparison of closing sections impossible
- Older filing also appears truncated at end ('see Part I,'), so full extent of removals at conclusion cannot be fully assessed
Risk Factors
- Added:
- Newer filing (2026-05-07) includes Item 1A Risk Factors page number as 52, compared to 43 in older filing (2026-02-09)
- Newer filing presents six-month period financial data (March 31, 2026 vs. 2025) in addition to three-month data
- Newer filing shows net loss from continuing operations of $(37) million for Q1 2026, compared to net income of $158 million in Q1 2025
- Newer filing shows net loss from discontinued operations of $(274) million for Q1 2026, compared to net income of $150 million in Q1 2025
- Newer filing includes 'Noncurrent Assets of Discontinued Operations' and 'Current liabilities of discontinued operations' and 'Noncurrent Liabilities of Discontinued Operations' line items in balance sheet
- Newer filing cash flow statement includes 'Distribution from spin-off entity, net' of $3,857 million in financing activities
- Newer filing cash flow statement includes 'Asset impairment charges' of $450 million and 'Impacts of debt extinguishment' of $(122) million in operating activities adjustments
- Newer filing includes discontinued operations sections in cash flow statement
- Newer filing shows 'Income from Discontinued Operations' as separate line item in income statement
- Removed:
- Older filing (2026-02-09) presented three-month period ended December 31 data (2025 vs. 2024); newer filing (2026-05-07) presents three-month and six-month periods ended March 31 data (2026 vs. 2025)
- Older filing balance sheet as of December 31, 2025; newer filing balance sheet as of March 31, 2026
- Older filing did not show discontinued operations in balance sheet line items
- Older filing cash flow statement for three months ended December 31, 2025; newer filing for six months ended March 31, 2026
- Reworded:
- Newer filing refers to 'former Biosciences and Diagnostic Solutions business' in Note 1 (filed 2026-05-07), while older filing (filed 2026-02-09) refers to 'Biosciences and Diagnostic Solutions business'
- Item numbering pages changed: Risk Factors moved from page 43 to page 52, and subsequent items renumbered accordingly in newer filing
- Notes:
- The two filings cover different reporting periods (Q1 2026 vs. Q4 2025), which explains significant differences in financial data beyond the spin-off event
- The older filing's Note 1 section text is truncated in the source material, limiting assessment of wording changes in that note
- Both filings describe the same February 9, 2026 transaction, but with different dates of filing providing different interim periods and updated financial statements
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 3 sells ($1M) — 3 selling insiders
- Last 90 days0 buys · 7 sells ($2M) — 4 selling insiders
- Last 180 days0 buys · 9 sells ($2M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-13. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BDX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 8 matched disclosures for BDX from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding BDX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 42,012,532
- Reported value $6,605,630,446
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BDX had 10,015,223 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BDX had 3.68% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.73 days to cover at the same settlement.
- Reported short interest (shares) 10,015,223
- Short interest (% of shares outstanding) 3.68%
- Prior settlement (shares) 10,381,615
- Reported change -3.53%
- Days to cover (reported) 5.73
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Baxter International (BAX)
- Boston Scientific (BSX)
- Medtronic (MDT)
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
- Abbott Laboratories (ABT)
- Stryker (SYK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BDX vs…
Becton Dickinson is found in…
BDX shows up in…
Frequently asked questions
What does Becton Dickinson (BDX) do?
Becton Dickinson is a global medical technology company engaged in the development, manufacture, and sale of a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. The company focuses on improving medical discovery, diagnostics, and the delivery of care through its comprehensive portfolio of healthcare solutions.
What sector is Becton Dickinson (BDX) in?
Becton Dickinson (BDX) is classified in the Health Care sector. Its industry is Medical Devices and Diagnostics. It trades on NYSE.
Does BDX pay a dividend?
Yes — Becton Dickinson (BDX) pays a dividend, with an indicated yield of about 1.59% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Becton Dickinson's (BDX) competitors?
Notable peers of Becton Dickinson (BDX) include Baxter International, Boston Scientific, Medtronic, Thermo Fisher Scientific and Danaher. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in BDX?
Yes — we hold 8 matched STOCK Act disclosures for BDX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Becton Dickinson (BDX) overbought or oversold right now?
Becton Dickinson (BDX) is currently in overbought territory (its 14-day RSI is 78, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BDX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.